Division of Family Planning, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; and the Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio.
Corresponding author: Aaron Lazorwitz, MD, MSCS, Division of Family Planning, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO; email: [email protected].
This study was primarily funded through an Investigator-Initiated Study grant from Merck Sharp & Dohme Corp [MISP#57073] to Dr. Teal. This work was also supported by NIH/NCATS Colorado CTSA Grant Number UL1 TR001082. Dr. Lazorwitz's time is supported by the NICHD K12 Women's Reproductive Health Research Scholar Program (grant number 5K12HD001271-18). Contents are the authors' sole responsibility and do not necessarily represent official NIH views. All funding sources listed had no involvement in the study design, collection, analysis, interpretation of data, writing of this report, or decision to submit this article for publication.
Financial Disclosure Dr. Teal serves on a Data Monitoring Board for a study funded by Merck and Co. and has served as a consultant for Bayer Healthcare. The University of Colorado Department of Obstetrics and Gynecology has received research funding from Bayer, Agile Therapeutics, Sebela, and Medicines360. The other authors did not report any potential conflicts of interest.
Presented at the Society of Family Planning Annual Meeting, held virtually, October 1–2, 2021.
The authors thank Judith Merritt, PhD, at the Q Squared Solutions laboratory for assisting with the etonogestrel analysis for this study.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/C600.
